Ribosomal protein L22 pseudogene 17 (RPL22P17)

Ribosomal protein L22 pseudogene 17 (RPL22P17) is a processed pseudogene, meaning it contains DNA sequences similar to ribosomal protein L22 but does not encode a functional protein[1][9][10]. Such pseudogenes are common relatives of ribosomal protein genes scattered across the human genome as remnants of gene duplication or retrotransposition events. RPL22P17 has no known biological function, disease association, nor clinical relevance as a therapeutic target in current research. It should not be confused with the active ribosomal protein L22, which is part of the 60S ribosomal subunit and implicated in cellular processes and disease[2][3][4]. Summary of key points: - RPL22P17 is not a receptor, enzyme, transporter, or other druggable protein; it is a pseudogene. - It is not currently associated with drug interactions, biomarkers, disease roles, or therapeutic safety concerns. - Its major alias is RPL22_7_1091; there are no clinical or biological functions attributed to it[10]. - Its designation as a "target molecule/receptor" in therapeutic contexts is incorrect. If precise information about the functional ribosomal protein L22 is needed, refer to RPL22, which is an actively transcribed gene involved in protein synthesis and associated with some cancers and cellular processes[2][3][4].

Other names

RPL22_7_1091